This review highlights the evolving understanding of supraventricular tachycardia mechanisms and the emerging roles of catheter ablation and anticoagulation therapies.
Answers are grounded in this paper and cite their sources.
Supports evolving anticoagulation use in nonrheumatic AF; leaves open optimal strategy for lone AF pending mature data.
In this review, the diagnosis and treatment of various supraventricular tachycardias are discussed. The atrial inhomogeniety and dispersion of refractoriness play as important a role in the genesis of atrial arrhythmias as does anisotropic conduction. Both inhomogeniety of conduction and anisotropy are more marked in the lower part of the right atrium than in its upper parts because of regional differences in the action potential duration. Three models of atrial flutter, ie, sterile pericarditis, surgically induced anatomic obstacle, and atrial dilatation are studied to further elucidate the mechanism of atrial flutter. Although reentry remains the most common mechanism, the mechanisms by which antiarrhythmic agents of different classes terminate atrial flutter may be quite different. Detailed activation mapping and localization of areas of slow conduction provide better insights into the mechanism of supraventricular tachycardias and a higher success yield for ablative procedures. The safety and efficacy of a given antiarrhythmic therapy (pharmacologic or nonpharmacologic) is significantly influenced by the underlying cardiac pathology. The results of trials of newer antiarrhythmic agents (eg, sotalol, propafenone) are presented, as well as the results of antitachycardia pacing and electrode catheter ablation techniques in treating supraventricular tachycardias. In general, both techniques are used for a very selected and well-investigated population of patients. However, more ablative techniques will emerge in the 1990s. Controversy about the role of anticoagulation in atrial fibrillation of nonrheumatic etiology continues; preliminary results of several randomized trials demonstrate that anticoagulation is beneficial. The role of aspirin in reducing thromboembolic complications in lone atrial fibrillation is promising.
No takes yet. Share an insight, caveat, or question.
Shenasa et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: